Skip to main content
SpringerLink
Log in

Safety and adverse effects during 24 hours after contrast-enhanced MRI with gadobenate dimeglumine (MultiHance®) in children

  • Original Article
  • Published:
Pediatric Radiology Aims and scope Submit manuscript

Abstract

Background

Gadolinium-based MR contrast agents have long been considered safe for routine diagnostic imaging. However, the advent of nephrogenic systemic fibrosis (NSF) among certain patients with severe renal insufficiency has brought the issue of safety into question. Nowhere is safety of greater concern than among children who frequently require multiple contrast-enhanced MRI examinations over an extended period of time.

Objective

To retrospectively evaluate the safety of gadobenate dimeglumine for contrast-enhanced (CE) MRI across a range of indications.

Materials and methods

Two hundred pediatric inpatients (age: 4 days to 15 years) underwent CE MRI as part of clinical routine. The children received a gadobenate dimeglumine dose of either 0.05 mmol/kg body weight (liver, abdominal imaging, musculoskeletal imaging, brain and other rare indications) or 0.1 mmol/kg bodyweight (cardiovascular imaging, MR-urography). Young (< 8 years) children with congenital heart disease were intubated and underwent MRA evaluation with controlled ventilation. Monitoring for adverse events was performed for at least 24 h after each gadobenate dimeglumine injection. Depending on clinical necessity, laboratory measurements and, in some cases, vital sign and ECG determinations were made before and after contrast injection. Safety was evaluated by age group, indication and dose administered.

Results

No clinically adverse events were reported among children who had one MRI scan only or among children who had several examinations. There were no changes in creatinine or bilirubin levels even in very young children.

Conclusions

No adverse events were recorded during the first 24 h following administration of gadobenate dimeglumine in 200 children.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Carr JJ (1994) Magnetic resonance contrast agents for neuroimaging. Safety issues. Neuroimaging Clin N Am 4:43–54

    PubMed  CAS  Google Scholar 

  2. Nelson KL, Gifford LM, Lauber-Huber C et al (1995) Clinical safety of gadopentetate dimeglumine. Radiology 196:439–443

    Google Scholar 

  3. Ekholm S, Jonsson E, Sandvik L et al (1996) Tolerance and efficacy on Omniscan (Gd-DTPA-BMA injection) in MR imaging of the central nervous system. Acta Radiologica 37:223–228

    PubMed  CAS  Google Scholar 

  4. Tresley RM, Stone LA, Fields N et al (1997) Clinical safety of serial monthly administrations of gadopentetate dimeglumine in patients with multiple sclerosis: implications for natural history and early-phase treatment trials. Neurology 48:832–835

    Google Scholar 

  5. Runge VM, Parker JR (1997) Worldwide clinical safety assessment of gadoteridol injection: an update. Eur Radiol 7(Suppl 5):243–245

    Article  PubMed  Google Scholar 

  6. Shellock FG, Kanal E (1999) Safety of magnetic resonance imaging contrast agents. J Magn Reson Imaging 10:477–484

    Article  PubMed  CAS  Google Scholar 

  7. Niendorf HP, Kallend D (1999) Gadolinium chelates: adverse reactions. In: Dawson P, Cosgrove DO, Grainger RG (eds) Textbook of contrast media. ISIS Medical Media, Oxford, UK, pp 323–332

    Google Scholar 

  8. Swan SK, Baker JF, Free R et al (1999) Pharmacokinetics, safety, and tolerability of gadoversetamide injection (OptiMARK) in subjects with central nervous system or liver pathology and varying degrees of renal function. J Magn Reson Imaging 9:317–321

    Article  PubMed  CAS  Google Scholar 

  9. Rubin DL, Desser TS, Semelka R et al (1999) A multicenter, randomized, double-blind study to evaluate the safety, tolerability, and efficacy of OptiMARK (gadoversetamide injection) compared with Magnevist (gadopentetate dimeglumine) in patients with liver pathology: results of a Phase III clinical trial. J Magn Reson Imaging 9:240–250

    Article  PubMed  CAS  Google Scholar 

  10. Runge VM (2000) Safety of approved MR contrast media for intravenous injection. J Magn Reson Imaging 12:205–213

    Article  PubMed  CAS  Google Scholar 

  11. Runge VM (2001) Safety of magnetic resonance contrast media. Top Magn Reson Imaging 12:309–314

    Article  PubMed  CAS  Google Scholar 

  12. De Ridder F, De Maeseneer M, Stadnik T et al (2001) Severe adverse reactions with contrast agents for magnetic resonance: clinical experience in 30,000 MR examinations. JBR-BTR 84:150–152

    Google Scholar 

  13. Kirchin MA, Runge VM (2003) Contrast agents for magnetic resonance imaging: safety update. Top Magn Reson Imaging 14:426–435

    Article  PubMed  Google Scholar 

  14. Baker JF, Kratz LC, Stevens GR et al (2004) Pharmacokinetics and safety of the MRI contrast agent gadoversetamide injection (OptiMARK) in healthy pediatric subjects. Invest Radiol 39:334–339

    Google Scholar 

  15. Bellin MF, Webb JA, Van Der Molen AJ et al (2005) Safety of MR liver specific contrast media. Eur Radiol 15:1607–1614

    Article  PubMed  Google Scholar 

  16. Webb JA, Thomsen HS, Morcos SK et al (2005) The use of iodinated and gadolinium contrast media during pregnancy and lactation. Eur Radiol 15:1234–1240

    Article  PubMed  Google Scholar 

  17. Knopp MV, Balzer T, Esser M et al (2006) Assessment of utilization and pharmacovigilance based on spontaneous adverse event reporting of gadopentetate dimeglumine as a magnetic resonance contrast agent after 45 million administrations and 15 years of clinical use. Invest Radiol 41:491–499, Erratum in: Invest Radiol 41:667

    Google Scholar 

  18. Garcia-Bournissen F, Shrim A, Koren G (2006) Safety of gadolinium during pregnancy. Can Fam Physician 52:309–310

    PubMed  Google Scholar 

  19. Bourrinet P, Martel E, El Amrani AI et al (2007) Cardiovascular safety of gadoterate meglumine (Gd-DOTA). Invest Radiol 42:63–77

    Article  PubMed  CAS  Google Scholar 

  20. Li A, Wong CS, Wong MK et al (2006) Acute adverse reactions to magnetic resonance contrast media--gadolinium chelates. Br J Radiol 79(941):368–371, Erratum in: Br J Radiol 80:145

    Google Scholar 

  21. Thomsen HS (2006) Nephrogenic systemic fibrosis: A serious late adverse reaction to gadodiamide. Eur Radiol 16:2619–2621

    Article  PubMed  Google Scholar 

  22. Marckmann P, Skov L, Rossen K et al (2006) Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17:2359–2362

    Article  PubMed  Google Scholar 

  23. Broome DR, Girguis MS, Baron PW et al (2007) Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR 188:586–592

    Google Scholar 

  24. Sadowski EA, Bennett LK, Chan MR et al (2007) Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 243:148–157

    Article  PubMed  Google Scholar 

  25. Kanal E, Barkovich AJ, Bell C et al (2007) ACR Blue Ribbon Panel on MR Safety. ACR guidance document for safe MR practices: 2007. AJR 188:1447–1474

    Google Scholar 

  26. Penfield JG, Reilly RF (2008) Nephrogenic systemic fibrosis risk: is there a difference between gadolinium-based contrast agents? Semin Dial 21:129–134

    Article  PubMed  Google Scholar 

  27. Kirchin MA, Pirovano G, Venetianer C et al (2001) Safety assessment of gadobenate dimeglumine (Multihance®): extended clinical experience from phase I studies to post-marketing surveillance. J Magn Reson Imaging 14:281–294

    Google Scholar 

  28. Shellock FG, Parker JR, Venetianer C et al (2006) Safety of gadobenate dimeglumine: summary of findings from clinical studies and post-marketing surveillance. Invest Radiol 41:500–509

    Google Scholar 

  29. Shellock FG, Parker JR, Pirovano G et al (2006) Safety characteristics of gadobenate dimeglumine: Clinical experience from intra- and interindividual comparison studies with gadopentetate dimeglumine. J Magn Reson Imaging 24:1378–1385

    Google Scholar 

  30. Bleicher AG, Kanal E (2008) Assessment of adverse reaction rates to a newly approved MRI contrast agent: review of 23,553 administrations of gadobenate dimeglumine. AJR 191:W307–W311

    Google Scholar 

  31. Herborn CU, Jäger-Booth I, Lodemann KP et al (2009) [Multicenter analysis of tolerance and clinical safety of the extracellular MR contrast agent gadobenate dimeglumine (MultiHance)]. Rofo 181:652–657

    Google Scholar 

  32. Pintaske J, Martirosian P, Graf H et al (2006) Relaxivity of Gadopentetate Dimeglumine (Magnevist), Gadobutrol (Gadovist), and Gadobenate Dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Invest Radiol 41:213–221, Erratum in: Invest Radiol 41:859

    Google Scholar 

  33. Bleicher AG, Kanal E (2008) A serial dilution study of gadolinium-based MR imaging contrast agents. AJNR 29:668–673

    Google Scholar 

  34. Giesel FL, von Tengg-Kobligk H, Wilkinson ID et al (2006) Influence of human serum albumin on longitudinal and transverse relaxation rates (R1 and R2) of magnetic resonance contrast agents. Invest Radiol 41:222–228

    Article  PubMed  CAS  Google Scholar 

  35. Spinazzi A, Lorusso V, Pirovano G et al (1999) Safety, tolerance, biodistribution and MR imaging enhancement of the liver with gadobenate dimeglumine. Acad Radiol 6:282–291

    Google Scholar 

  36. Grazioli L, Morana G, Federle MP et al (2001) Focal nodular hyperplasia: morphological and functional information from MR imaging with gadobenate dimeglumine. Radiology 221:731–739

    Article  PubMed  CAS  Google Scholar 

  37. Schneider G, Maas R, Schultze Kool L et al (2003) Low-dose gadobenate dimeglumine versus standard dose gadopentetate dimeglumine for contrast-enhanced magnetic resonance imaging of the liver: an intra-individual crossover comparison. Invest Radiol 38:85–94

    Google Scholar 

  38. Grazioli L, Morana G, Kirchin MA et al (2005) Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine – enhanced MR imaging: prospective study. Radiology 236:166–177

    Google Scholar 

  39. Colosimo C, Demaerel P, Tortori-Donati P et al (2005) Comparison of gadobenate dimeglumine (Gd-BOPTA) with gadopentetate dimeglumine (Gd-DTPA) for enhanced MR imaging of brain and spine tumors in pediatric subjects. Pediatr Radiol 35:501–510

    Article  PubMed  Google Scholar 

  40. Savory DJ (1990) Reference ranges for serum creatinine in infants, children and adolescents. Ann Clin Biochem 27(Pt 2):99–101

    PubMed  CAS  Google Scholar 

  41. Knopp MV, Giesel FL, von Tengg-Kobligk H et al (2003) Contrast-enhanced MR angiography of the run-off vasculature: intraindividual comparison of gadobenate dimeglumine with gadopentetate dimeglumine. J Magn Reson Imaging 17:694–702

    Article  PubMed  Google Scholar 

  42. Gerretsen SC, le Maire TF, Miller S et al (2010) Multicenter, double-blind, randomized, intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for MR angiography of peripheral arteries. Radiology 255:988–1000

    Article  PubMed  Google Scholar 

  43. Bültmann E, Erb G, Kirchin MA et al (2008) Intra-individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for contrast-enhanced MR angiography of the supraaortic vessels at 3 Tesla. Invest Radiol 43:695–702

    Google Scholar 

  44. Pediconi F, Fraioli F, Catalano C et al (2003) Gadobenate dimeglumine (Gd-BOPTA) vs. gadopentetate dimeglumine (Gd-DTPA) for contrast-enhanced magnetic resonance angiography (MRA): improvement in intravascular signal intensity and contrast to noise ratio. Radiol Med 106:87–93

    PubMed  Google Scholar 

  45. Prokop M, Schneider G, Vanzulli A et al (2005) Contrast-enhanced MR Angiography of the renal arteries: blinded multicenter crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. Radiology 234:399–408

    Google Scholar 

  46. Stein PD, Chenevert TL, Fowler SE et al (2010) Gadolinium-enhanced magnetic resonance angiography for pulmonary embolism: a multicenter prospective study (PIOPED III). Ann Intern Med 152:434–443

    Article  PubMed  Google Scholar 

  47. Woodard PK, Chenevert TL, Sostman HD et al (2012) Signal quality of single dose gadobenate dimeglumine pulmonary MRA examinations exceeds quality of MRA performed with double dose gadopentetate dimeglumine. Int J Cardiovasc Imaging 28:295–301

    Article  PubMed  Google Scholar 

  48. Achenbach M, Figiel JH, Burbelko M et al (2010) Prospective comparison of image quality and diagnostic accuracy of 0.5 molar gadobenate dimeglumine and 1.0 molar gadobutrol in contrast-enhanced run-off magnetic resonance angiography of the lower extremities. J Magn Reson Imaging 32:1166–1171

    Google Scholar 

  49. Balci NC, Inan N, Anik Y et al (2006) Low-dose gadobenate dimeglumine versus standard-dose gadopentate dimeglumine for delayed contrast-enhanced cardiac magnetic resonance imaging. Acad Radiol 13:833–839

    Google Scholar 

  50. Li Y, Li X, Li D et al (2012) Multicenter, intra-individual comparison of single dose gadobenate dimeglumine and double dose gadopentetate dimeglumine for MR Angiography of the supra-aortic arteries (the supra-aortic VALUE study). AJNR. doi:10.3174/ajnr.A3298

  51. Tomasian A, Salamon N, Lohan DG et al (2008) Supraaortic arteries: contrast material dose reduction at 3.0-T high-spatial-resolution MR angiography–feasibility study. Radiology 249:980–990

    Google Scholar 

  52. Penfield JG (2008) Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents. Pediatr Nephrol 23:2121–2129

    Article  PubMed  Google Scholar 

  53. Mendichovszky IA, Marks SD, Simcock CM et al (2008) Gadolinium and nephrogenic systemic fibrosis: time to tighten practice. Pediatr Radiol 38:489–496

    Google Scholar 

  54. Pirovano G, Munley J, Schultz C et al (2012) Nephrogenic systemic fibrosis: a review of published cases and results from three prospective observational studies. Presented at European Congress of Radiology, Vienna, Austria; March 1–5.

Download references

Author information

Authors and Affiliations

  1. Homburg University Hospital, Homburg, Saar, Germany

    Guenther Schneider, Hellmut Schürholz, Arno Bücker & Peter Fries

  2. Bracco Imaging SpA, Milan, Italy

    Miles A. Kirchin

Authors
  1. Guenther Schneider
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hellmut Schürholz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Miles A. Kirchin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Arno Bücker
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Peter Fries
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Guenther Schneider.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schneider, G., Schürholz, H., Kirchin, M.A. et al. Safety and adverse effects during 24 hours after contrast-enhanced MRI with gadobenate dimeglumine (MultiHance®) in children. Pediatr Radiol 43, 202–211 (2013). https://doi.org/10.1007/s00247-012-2498-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00247-012-2498-8

Keywords

Search

Navigation